ZTS logo

Zoetis (ZTS)

Profile

Full Name

Zoetis Inc.

Ticker Symbol

ZTS

Exchange

NYSE

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

February 1, 2013

Indexes

S&P 500

Website

http://www.zoetis.com

Employees

13800

Key Details

Price

$149.44(+1.66%)

Market cap

Last Dividend

$0.50

TTM Dividend yield

1.20%

Annual revenue

$9.26B(+8.33% YoY)

Annual EPS

$5.47(+7.89% YoY)

PE ratio

27.32

Next earnings date

May 6, 2025

Next ex-dividend date

Apr 21, 2025

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$149.44
ZTS price is $149.44

30-Day Relative Volume

1.02
ZTS 30-day relative volume is 1.02

Price Performance

Price Most recent change

+1.66%
ZTS price was up +1.66% on Apr 11, 2025

Price YTD change

-8.28%
ZTS price is down -8.28% since January 1st

Price 1-year change

-8.17%
ZTS price is down -8.17% year-on-year

Price 3-year change

-22.37%
ZTS price is down -22.37% over the past 3 years

Price Range

Price All-time high

$249.27
ZTS price is currently -40.05% below its historical high of $249.27

Price 3-year low

$124.15
ZTS price is currently +20.37% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$66.92B
ZTS market capitalization is $66.92 billion

Market cap 3-year change

-26.23%
ZTS market capitalization is down -26.23% over the past 3 years

Market cap All-time high

$116.88B
ZTS market capitalization is currently -42.74% below its historical high of $116.88 billion

Market cap sector rank

97.78%
ZTS market capitalization is higher than 97.78% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-2%
ZTS shares outstanding is down -2% year-on-year

Shares Outstanding 3-Year Change

-4.97%
ZTS shares outstanding is down -4.97% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.52
ZTS beta is 0.52

200-day SMA

$175.58
ZTS price is currently -14.89% below its 200-day simple moving average

50-day SMA

$163.70
ZTS price is currently -8.71% below its 50-day simple moving average

RSI

39.12
ZTS 14-day relative strength index is 39.12

Volume

1.02
ZTS 30-day relative volume is 1.02

ATR

$6.20
ZTS average true range is $6.20

10-day Historical Volatility

53.41%
ZTS 10-day historical volatility is 53.41%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$0.50
ZTS last dividend was $0.50 per share, with an ex-dividend date of January 21, 2025

Next Dividend

$0.50
ZTS has announced a dividend of $0.50 per share, with an ex-dividend date set for April 21, 2025

Dividend per share

Dividend per share

$1.73
ZTS annual dividend per share is $1.73

Dividend per share Sector Rank

63.95%
ZTS annual dividend per share is higher than 63.95% of companies in Healthcare sector

Dividend per share 1-Year Change

+15.2%
ZTS annual dividend per share is up +15.2% year-on-year

Dividend per share 3-Year Change

+72.8%
ZTS annual dividend per share is up +72.8% over the past 3 years

Dividend yield

Dividend yield

1.16%
ZTS annual dividend yield is 1.16%

Dividend yield Sector Rank

31.76%
ZTS annual dividend yield is higher than 31.76% of companies in Healthcare sector

Other

Payout ratio

31.62%
ZTS annual payout ratio is 31.62%

Dividends paid

$786.00M
ZTS annual dividends paid is $786.00 million

Free cash flow

$2.30B
ZTS annual free cash flow is $2.30 billion

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$9.26B
ZTS annual revenue is $9.26 billion

Revenue Analysts estimate

$9.37B
ZTS annual revenue is currently -1.17% lower than the consensus analysts' forecast

Revenue 1-year change

+8.33%
ZTS annual revenue is up +8.33% year-on-year

Revenue Sector rank

93.84%
ZTS annual revenue is higher than 93.84% of companies in Healthcare sector

EPS

EPS

$5.47
ZTS annual earnings per share is $5.47

EPS Analysts estimate

$6.09
ZTS annual earnings per share is currently -10.17% lower than the consensus analysts' forecast

EPS 1-year change

+7.89%
ZTS annual earnings per share is up +7.89% year-on-year

EPS Sector rank

95.95%
ZTS annual earnings per share is higher than 95.95% of companies in Healthcare sector

Profit

Gross profit

$6.54B
ZTS annual gross profit is $6.54 billion

Gross margin

70.62%
ZTS annual gross profit margin is 70.62%

Operating profit

$3.39B
ZTS annual operating income is $3.39 billion

Operating margin

36.65%
ZTS annual operating profit margin is 36.65%

Net income

$2.49B
ZTS annual net profit is $2.49 billion

Net margin

26.86%
ZTS annual net profit margin is 26.86%

Expenses

Total expenses

$5.86B
ZTS annual total expenses is $5.86 billion

Operating expenses

$3.15B
ZTS annual total operating expenses is $3.15 billion

Cost of goods sold

$2.72B
ZTS annual cost of goods sold is $2.72 billion

Selling, general & administrative expenses

$2.32B
ZTS annual SGA is $2.32 billion

Depreciation and amortization

$497.00M
ZTS annual depreciation & amortization is $497.00 million

Interest expense

$225.00M
ZTS annual interest expense is $225.00 million

Income tax

$637.00M
ZTS annual income tax is $637.00 million

EBIT & EBITDA

EBIT

$3.36B
ZTS annual earnings before interest & taxes is $3.36 billion

EBITDA

$3.85B
ZTS annual EBITDA is $3.85 billion

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$14.24B
ZTS annual total assets is $14.24 billion

Non current assets

$8.25B
ZTS annual long term assets is $8.25 billion

Current assets

$5.99B
ZTS annual total current assets is $5.99 billion

Cash and cash equivalents

$1.99B
ZTS annual cash & cash equivalents is $1.99 billion

Accounts receivable

$1.32B
ZTS annual accounts receivable is $1.32 billion

Inventory

$2.31B
ZTS annual inventory is $2.31 billion

Liabilities

Total liabilities

$9.47B
ZTS annual total liabilities is $9.47 billion

Long term liabilities

$6.05B
ZTS annual total long term liabilities is $6.05 billion

Current liabilities

$3.41B
ZTS annual total current liabilities is $3.41 billion

Accounts payable

$433.00M
ZTS annual accounts payable is $433.00 million

Debt

Total debt

$6.74B
ZTS annual total debt is $6.74 billion

Total debt 1-year change

-0.16%
ZTS annual total debt is down -0.16% year-on-year

Long term debt

$5.39B
ZTS annual long term debt is $5.39 billion

Short term debt

$1.35B
ZTS annual short term debt is $1.35 billion

Equity & Capital

Shareholders equity

$4.77B
ZTS annual stockholders equity is $4.77 billion

Book value

$4.77B
ZTS annual book value is $4.77 billion

Retained earnings

$11.97B
ZTS annual retained earnings is $11.97 billion

Working capital

$2.57B
ZTS annual working capital is $2.57 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$2.95B
ZTS annual cash flow from operations is $2.95 billion

Cash from operations 1-year change

+25.5%
ZTS annual cash flow from operations is up +25.5% year-on-year

Cash from investing

-$315.00M
ZTS annual cash flow from investing activities is -$315.00 million

Cash from investing 1-year change

+59.46%
ZTS annual cash flow from investing activities is up +59.46% year-on-year

Cash from financing

-$2.66B
ZTS annual cash flow from financing activities is -$2.66 billion

Cash from financing 1-year change

+14.44%
ZTS annual cash flow from financing activities is up +14.44% year-on-year

CAPEX

CAPEX

$655.00M
ZTS annual capital expenditures is $655.00 million

CAPEX 1-year change

-10.52%
ZTS annual capital expenditures is down -10.52% year-on-year

Free Cash Flow

Free cash flow

$2.30B
ZTS annual free cash flow is $2.30 billion

Free cash flow 1-year change

+41.76%
ZTS annual free cash flow is up +41.76% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

70.62%
ZTS annual gross profit margin is 70.62%

Operating margin

36.65%
ZTS annual operating profit margin is 36.65%

Net margin

26.86%
ZTS annual net profit margin is 26.86%

ROA & ROE

ROA

17.43%
ZTS annual return on assets is 17.43%

ROE

50.94%
ZTS annual return on equity is 50.94%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

27.32
ZTS price to earnings ratio is 27.32

PE ratio Sector rank

57.35%
ZTS price to earnings ratio is higher than 57.35% of companies in Healthcare sector

PB Ratio

PB ratio

14.03
ZTS price to book ratio is 14.03

PB ratio Sector rank

95.56%
ZTS price to book ratio is higher than 95.56% of companies in Healthcare sector

PS Ratio

PS ratio

7.23
ZTS price to sales ratio is 7.23

PS ratio Sector rank

74.74%
ZTS price to sales ratio is higher than 74.74% of companies in Healthcare sector

Enterprise value

Enterprise value

$71.68B
ZTS enterprise value is $71.68 billion

Enterprise value Sector rank

97.69%
ZTS enterprise value is higher than 97.69% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

18.59
ZTS EV/EBITDA is 18.59

EV/EBITDA Sector rank

90.63%
ZTS EV/EBITDA is higher than 90.63% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

1.75
ZTS annual current ratio is 1.75

Quick ratio

1.08
ZTS annual quick ratio is 1.08

Leverage

Debt to equity

1.38
ZTS annual debt to equity ratio is 1.38

Interest coverage ratio

14.92
ZTS annual interest coverage ratio is 14.92

Risk & Stability

Piotroski F-Score

8
ZTS piotroski f-score is 8

Altman Z-Score

7.06
ZTS altman z-score is 7.06

Analyst ratings

Recent major analysts updates

Feb 27, 25 Piper Sandler
Overweight
Feb 14, 25 Morgan Stanley
Overweight
Feb 14, 25 Barclays
Overweight
Feb 10, 25 Piper Sandler
Overweight
Jan 29, 25 Morgan Stanley
Overweight
Jan 7, 25 Stifel
Buy
Dec 10, 24 UBS
Neutral
Dec 2, 24 Leerink Partners
Outperform
Oct 11, 24 JP Morgan
Overweight
Sep 18, 24 Stifel
Buy

Institutional Ownership

Similar stocks

GSK logo
GSK (GSK)
REGN logo
Regeneron Pharmaceuticals (REGN)
BDX logo
Becton Dickinson and Company (BDX)
HCA logo
HCA Healthcare (HCA)
MCK logo
McKesson (MCK)
CVS logo
CVS Health (CVS)
HLN logo
Haleon (HLN)
ALC logo
Alcon (ALC)
TAK logo
Takeda Pharmaceutical Company Limited (TAK)
  • What is the ticker symbol for Zoetis?
  • Does Zoetis pay dividends?
  • What sector is Zoetis in?
  • What industry is Zoetis in?
  • What country is Zoetis based in?
  • When did Zoetis go public?
  • Is Zoetis in the S&P 500?
  • Is Zoetis in the NASDAQ 100?
  • Is Zoetis in the Dow Jones?
  • When was Zoetis's last earnings report?
  • When does Zoetis report earnings?
  • Should I buy Zoetis stock now?

What is the ticker symbol for Zoetis?

The ticker symbol for Zoetis is NYSE:ZTS

Does Zoetis pay dividends?

Yes, Zoetis pays dividends. The last payment was $0.50, with an ex-dividend date on January 21, 2025

What sector is Zoetis in?

Zoetis is in the Healthcare sector

What industry is Zoetis in?

Zoetis is in the Drug Manufacturers - Specialty & Generic industry

What country is Zoetis based in?

Zoetis is headquartered in United States

When did Zoetis go public?

Zoetis's initial public offering (IPO) was on February 1, 2013

Is Zoetis in the S&P 500?

Yes, Zoetis is included in the S&P 500 index

Is Zoetis in the NASDAQ 100?

No, Zoetis is not included in the NASDAQ 100 index

Is Zoetis in the Dow Jones?

No, Zoetis is not included in the Dow Jones index

When was Zoetis's last earnings report?

Zoetis's most recent earnings report was on Feb 13, 2025

When does Zoetis report earnings?

The next expected earnings date for Zoetis is May 6, 2025

Should I buy Zoetis stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page